Third Wave Technologies, Inc. engages in the development and marketing of molecular diagnostic products for various DNA and RNA analysis applications. It provides physicians and researchers with molecular solutions for the analysis and treatment of disease. The company offers products based proprietary Invader chemistry, a technology used in women’s health, infectious disease, genetics and pharmacogenetics, and oncology segments. Third Wave principally offers inVitro diagnostic devices and analyte specific reagents. The company’s analyte specific reagents allow laboratories to create assays to perform hepatitis C virus genotyping, inherited disorders testing, and a host of other mutations associated with genetic predispositions and other diseases. Third Wave also develops various DNA and RNA analysis products for the research and agricultural biotechnology markets. Its customers include clinical laboratories, pharmaceutical and biotechnology companies, academic research centers, and health care providers. Third Wave sells its products through a combination of direct sales personnel who focuses primarily on the clinical market, as well as through collaborative relationships in the United States and Europe. The company was founded in 1993 and is headquartered in Madison, Wisconsin.